Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

April 16, 2024

https://www.globenewswire.com/news-release/2024/04/16/2863611/0/en/Palisade-Bio-Successfully-Demonstrates-Bioactivation-of-PALI-2108-In-Ex-Vivo-Study-of-Normal-Healthy-and-Ulcerative-Colitis-Patients-Stool.html

Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC)

Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq:PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.